Find out what words our team use to describe our company in one word.
Hear from members of the team about what brought them to Bicycle Therapeutics, what makes us different and our workplace culture.
To mark this day, some of our team explain what inspired their dedication to science and what brought them to Bicycle Therapeutics.
Nick explains why he joined Bicycle, what makes Bicycle different from other biotechs, and his current role as CSO.
Kevin discusses all things Bicycle, the cutting-edge biotechnology we are pioneering, and how our novel bicyclic peptide technology can be utilized for the potential treatment of cancers and beyond.
Kevin provides a clinical update, discussing the interim BT5528 Phase I clinical trial results and preliminary results from ongoing BT8009 Phase I clinical trial.
Kevin gives an overview of the exclusive license and collaboration agreement Bicycle has entered with Ionis to develop targeted oligonucleotide therapeutics.
Stay up to date with the team and learn how we are working to help patients waiting for new treatments. Follow us on Twitter, connect with us on LinkedIn.
